

References

I-199

1. Ilumya™ (tildrakizumab-asmn) injection, for subcutaneous use [package insert]. Sun Pharmaceutical Industries, Inc. Cranbury, NJ. Revised 04/2024.
2. Micromedex DrugDex Compendium®. 2024. Tildrakizumab.
3. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Tildrakizumab.
4. Blauvelt A, Reich K, Papp K, et al. Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Trials. *Br J Dermatol*. 2018;179(3):615-622.
5. Menter A, Gottlieb A, Feldman S, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol*. 2018;58(5):826-850.
6. Menter A, Strober B, Kaplan D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80:1029-1072.
7. Reich K, Papp K, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. *Lancet*. 2017;390(10091):276-288.
8. Tildrakizumab-asmn In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 10, 2024.
9. Elewski B, Menter A, Crowley J, et al. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. *J Dermatolog Treat*. 2020;31(8):763-768.
10. D'Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. *Lancet*. 2022;399(10340):2015-2030.
11. Feagan BG, Panés J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. *Lancet Gastroenterol Hepatol*. 2018;3(10):671-680.
12. Micromedex DrugDex Compendium®. 2024. Risankizumab-rzaa.
13. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Risankizumab.
14. Skyrizi® (risankizumab-rzaa) injection, for subcutaneous or intravenous use [package insert]. AbbVie Inc., North Chicago, IL. Revised 06/2024.
15. Omvoh™ (mirikizumab-mrkz) injection, for intravenous or subcutaneous use [package insert]. Eli Lilly and Co., Indianapolis, IN. Revised 04/2024.
16. Micromedex DrugDex Compendium®. 2024. Mirikizumab-mrkz

17. Clinical PharmacologyTM Compendium. 2024. Tampa FL: Gold Standard, Inc.
Mirikizumab
18. Mirikizumab-mrkz In: AHFS Drug Information Online Electronic Medical Library.
Bethesda, MD: American Society of Health-System Pharmacists. Updated July 9, 2024.
19. Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study.
Gastroenterol Hepatol (N Y). 2022;18(4):7-8.
20. Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-2 study.
Gastroenterol Hepatol (N Y). 2022;18(7):3-4.
21. D'Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2023;388(26):2444-2455.